Activated ALK Collaborates with MYCN in Neuroblastoma Pathogenesis
- 20 March 2012
- journal article
- research article
- Published by Elsevier BV in Cancer Cell
- Vol. 21 (3), 362-373
- https://doi.org/10.1016/j.ccr.2012.02.010
Abstract
No abstract availableKeywords
This publication has 43 references indexed in Scilit:
- Genetically engineered murine models – Contribution to our understanding of the genetics, molecular pathology and therapeutic targeting of neuroblastomaSeminars in Cancer Biology, 2011
- The Neuroblastoma-Associated F1174L ALK Mutation Causes Resistance to an ALK Kinase Inhibitor in ALK-Translocated CancersCancer Research, 2010
- Crizotinib inALK-Rearranged Inflammatory Myofibroblastic TumorThe New England Journal of Medicine, 2010
- Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung CancerThe New England Journal of Medicine, 2010
- Meta-analysis of Neuroblastomas Reveals a Skewed ALK Mutation Spectrum in Tumors with MYCN AmplificationClinical Cancer Research, 2010
- Recent Advances in NeuroblastomaThe New England Journal of Medicine, 2010
- Molecular pathogenesis of peripheral neuroblastic tumorsOncogene, 2010
- MYCN Promotes the Expansion of Phox2B-Positive Neuronal Progenitors to Drive Neuroblastoma DevelopmentThe American Journal of Pathology, 2009
- Activating mutations in ALK provide a therapeutic target in neuroblastomaNature, 2008
- Oncogenic mutations of ALK kinase in neuroblastomaNature, 2008